Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2 - Abraham, Prema; Yue, Huibin; Wilson, Laura (American journal of ophthalmology, 2010)
Keywords: Aged; Aged, 80 and over; Angiogenesis Inhibitors - administration & dosage; Angiogenesis Inhibitors - adverse effects; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal, Humanized; Biological and medical sciences; Choroidal Neovascularization - drug therapy; Choroidal Neovascularization - etiology; Choroidal Neovascularization - physiopathology; Confidence intervals; Cross-Over Studies; Diabetic retinopathy; Double-Blind Method; Female; Health Insurance Portability & Accountability Act 1996-US; Hemorrhage; Humans; Injections; Macular degeneration; Macular Degeneration - complications; Macular Degeneration - drug therapy; Macular Degeneration - physiopathology; Male; Medical imaging; Medical sciences; Middle Aged; Miscellaneous; Occult sciences; Ophthalmology; Photodynamic therapy; Ranibizumab; Retina; Retinopathies; Retreatment; Standard deviation; Treatment Outcome; Vascular endothelial growth factor; Visual Acuity - physiology; Vitreous Body; South San Francisco California; California; Immunomodulator; Eye disease; Retinopathy; Vascular endothelium growth factor; Ranibizumab; Mask; Clinical trial; Age related macular degeneration; Monoclonal antibody; Neovascularization; Ophthalmology; Antiangiogenic agent